KT-253 by Kymera Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KT-253 overview

KT-253 is under development for the treatment of solid tumors, uveal melanoma, hematological malignancies such as acute lymphoblastic leukemia, merkel cell carcinoma,  relapsed and refractory acute myeloid leukemia (AML), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and lymphoma. The drug candidate is a heterobifunctional PROTAC (proteolysis targeting chimera) which acts as a selective degrader of MDM2 with functioning (WT) p53. It is administered through intravenous route.

Kymera Therapeutics overview

Kymera Therapeutics (Kymera) is a biopharmaceutical company that discovers and develops small molecule therapeutics for protein degradation. The company’s pipeline includes IRAK4 for the treatment of atopic dermatitis, hidradenitis suppurativa, macrophage activation syndrome, general pustular psoriasis and rheumatoid arthritis, IRAKIMiD for the treatment of MYD88 tumor, STAT3 for PTCL, LGL-L, CTCL and Solid Tumors. Kymera’s other pipeline includes MDM2 for Liquid and Solid Tumors. The company also utilizes Pegasus a drug discovery platform that allows the discovery of selective small molecule protein degraders against disease-causing proteins throughout the body. Kymera is headquartered in Watertown, Massachusetts, the US.

For a complete picture of KT-253’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.